Macugen (pegaptanib sodium injection)

Please note: Bausch + Lomb is currently unable to fulfill distribution requests for Macugen (pegaptanib sodium injection) in the United States. This situation relates to the product's future contract manufacturing and supply and does not affect product already in distribution. We will continue work to resume production as soon as possible. We apologize for any inconvenience this may cause you, and will provide an update as appropriate. If you have any questions or concerns, please call 1-800-321-4576.

Macugen (pegaptanib sodium injection) is a treatment for the eye condition known as wet age related macular degeneration (wet AMD), and it is specifically designed to prevent growth of the weak blood vessels that can begin leaking and cause damage to the retina.

Please click to view the Macugen Prescribing Information.

Indication

Macugen (pegaptanib sodium injection) is approved to treat Wet Age-Related Macular Degeneration, a condition that could affect your vision due to leaking blood vessels in your eye.

Important Safety Information

  • You should not receive Macugen (pegaptanib sodium injection) if you have an infection in or around your eye or if you are allergic to pegaptanib sodium or any of the other ingredients. Contact your doctor immediately if you have unusual swelling, rash, or difficulty breathing after having a Macugen injection.
  • In the days following Macugen administration, you may be at risk for the development of endophthalmitis (inflammation of the inner coats of the eye due to an infection). If the eye becomes red, sensitive to light, painful, or develops a change in vision, contact your doctor immediately so you can be treated early if an infection occurs.
  • Macugen can increase eye pressure within 30 minutes after it is injected into your eye. Your doctor may do some extra tests after your injection to make sure there are no complications or problems.
  • Serious side effects related to the injection procedure have been seen in patients receiving eye injections such as Macugen. These include endophthalmitis, a separation in the retina referred to as retinal detachment, and cataract. Less than 1% of injections have caused a serious side effect.
  • The following side effects were reported by 10-40% of patients treated with Macugen for up to two years in clinical studies: eye swelling, blurred vision, cataract, increased redness in the white of the eye, discharge from the eye, eye irritation, eye pain, high blood pressure, increased eye pressure, eye discomfort, visual disturbances, burning sensation, redness, light sensitivity, and vision loss.

Click here for Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

MAC.0026.USA.15